



## Structured clinical documentation in the electronic medical record to improve quality and to support practice-based research in epilepsy

\*Jaishree Narayanan, \*Sofia Dobrin, \*Janet Choi, \*Susan Rubin, \*Anna Pham, \*Vimal Patel, \*Roberta Frigerio, †Darryck Maurer, †Payal Gupta, †Lourdes Link, ‡Shaun Walters, ‡Chi Wang, ‡Yuan Ji, and \*Demetrius M. Maraganore

*Epilepsia*, 58(1):68–76, 2017  
doi: 10.1111/epi.13607

### SUMMARY

**Objective:** Using the electronic medical record (EMR) to capture structured clinical data at the point of care would be a practical way to support quality improvement and practice-based research in epilepsy.

**Methods:** We describe our stepwise process for building structured clinical documentation support tools in the EMR that define best practices in epilepsy, and we describe how we incorporated these toolkits into our clinical workflow.

**Results:** These tools write notes and capture hundreds of fields of data including several score tests: Generalized Anxiety Disorder-7 items, Neurological Disorders Depression Inventory for Epilepsy, Epworth Sleepiness Scale, Quality of Life in Epilepsy-10 items, Montreal Cognitive Assessment/Short Test of Mental Status, and Medical Research Council Prognostic Index. The tools summarize brain imaging, blood laboratory, and electroencephalography results, and document neuromodulation treatments. The tools provide Best Practices Advisories and other clinical decision support when appropriate. The tools prompt enrollment in a DNA biobanking study. We have thus far enrolled 231 patients for initial visits and are starting our first annual follow-up visits and provide a brief description of our cohort.

**Significance:** We are sharing these EMR tools and captured data with other epilepsy clinics as part of a Neurology Practice Based Research Network, and are using the tools to conduct pragmatic trials using subgroup-based adaptive designs.

**KEY WORDS:** Electronic medical record, Epilepsy, Structured clinical documentation support, Clinical decision support, Outcomes, Best practices, Pragmatic trials.



Dr. Jaishree Narayanan is Director, Epilepsy Program, Department of Neurology, NorthShore, University HealthSystem.

Documentation is an indispensable part of medical practice. This is especially important in neurology because many complex disorders change over time. Serial documentation of the clinical course guides treatment and safety measures. In the subspecialty of epilepsy, it is immensely useful to

have details of seizure frequency, seizure severity, brain imaging, electroencephalography (EEG) changes, response to antiseizure medications, drug adverse effects, medication changes, as well as other treatments (e.g., surgeries, devices) routinely documented and summarized.

Accepted October 10, 2016; Early View publication November 19, 2016.

\*NorthShore Neurological Institute, NorthShore University HealthSystem, Evanston, Illinois, U.S.A.; †Health Information Technology, NorthShore University HealthSystem, Evanston, Illinois, U.S.A.; and ‡Research Institute, NorthShore University HealthSystem, Evanston, Illinois, U.S.A.

Address correspondence to Demetrius M. Maraganore, Department of Neurology, NorthShore Neurological Institute, NorthShore University Health System, 2650 Ridge Ave., Evanston, IL 60201, U.S.A. E-mail: dmaraganore@northshore.org

© 2016 The Authors. *Epilepsia* published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

### KEY POINTS

- The EMR can capture structured clinical data and provide clinical decision support to promote quality improvement and practice-based research in epilepsy
- We have built into our EMR structured clinical documentation support (SCDS) tools that conform to best practices in epilepsy
- SCDS tools write notes and capture hundreds of fields of data including several score tests; brain imaging, blood laboratory, and electroencephalography results; and treatment outcomes
- We are sharing our EMR tools and data with other sites, and using the tools to conduct pragmatic trials using the EMR and subgroup-based adaptive designs

Epilepsy affects 4% of the population over the lifetime.<sup>1</sup> It can have significant negative effects on quality of life.<sup>2</sup> Although the American Academy of Neurology (AAN) has proposed quality measures for the management of epilepsy, it is not clear if these are routinely implemented or how often they are being followed. It is also unclear whether compliance to these or other quality measures improves epilepsy outcomes.<sup>3</sup>


The mainstay of epilepsy treatment is medications. There are multiple antiepileptic medications available to prescribe, but there is little evidence to guide the selection of one agent rather than another in an individual patient, excepting when there are clear contraindications. Comparative effectiveness studies are available, but they are either

observational (limited by possible selection biases) or structured literature reviews (indirectly comparing randomized placebo-control trials in highly selected patients).<sup>4-9</sup> There have been no point of care trials with head to head comparisons of available treatments including not only seizure control, but also cognitive function, mood, and quality of life.

Information documented in the electronic medical record (EMR) for patients with epilepsy is typically unstructured and not discretized, and hence cannot be used efficiently to implement quality measures or to support research. To this end, the NorthShore University HealthSystem (NorthShore) Department of Neurology built within its commercial EMR system (Epic) structured clinical documentation support (SCDS) tools that navigate care according to best practices, generate notes at initial and annual follow-up visits with simple mouse clicks through electronic forms, and capture several hundred fields of epilepsy data per office visit.<sup>10</sup> The clinical decision support (CDS) features of our epilepsy toolkit ensure that care is safely within the parameters of AAN quality guidelines, and support enrollment into clinical research studies (e.g., DNA biobank, pragmatic trials using subgroup-based adaptive designs). The tools and the data captured are being shared with other neurology practices using the same EMR system, creating a Neurology Practice Based Research Network (NPBRN). The purpose of this article is to describe our epilepsy toolkit and its current uses.

### METHODS

Figure 1 illustrates our stepwise process of quality improvement and practice-based research using the EMR, which is also described in detail below.



**Figure 1.**

Structured clinical document support toolkit. Quality improvement and practice-based research in epilepsy using the electronic medical record (EMR) consists of a stepwise progression from the development and implementation of a structured clinical documentation support (SCDS) toolkit (including note writing and electronic data capture); to enrollment reports; to data quality reports (and data cleaning); to descriptive reports of cohort characteristics; to quality improvement projects (including the creation of benchmark data and quality improvement dashboards); to the use of clinical decision support tools (to hardwire patient safety and improved outcomes); to other research (e.g., biobanking of DNA and the association of genotypes with longitudinal outcomes, pragmatic trials using subgroup adaptive design). The EMR provides a framework for measuring and impacting the three dimensions of quality improvement: structure, process, and outcomes.

*Epilepsia* © ILAE

## Content building

Neurologists in the epilepsy program at NorthShore met every 2 weeks for a period of 3 months to standardize epilepsy office visit types (initial visits, annual visits) according to best practices. We developed consensus on definitions of epilepsy and related disorders, the outcomes of interest to clinicians and patients, valid and feasible outcome measures for point of care assessments, and factors known to influence the outcomes and measures. This was done in conjunction with the development of similar toolkits in other fields of neurology clinical practice.<sup>10</sup> We consulted the AAN epilepsy quality measures, the National Institute of Neurological Disorders and Stroke (NINDS) common data elements pertaining to epilepsy, and the International League Against Epilepsy (ILAE) guidelines and classifications.<sup>3,11–15</sup> We included measures of anxiety (Generalized Anxiety Disorder-7, GAD-7),<sup>16</sup> depression (Neurological Disorders Depression Inventory for Epilepsy, NDDIE),<sup>17</sup> sleepiness (Epworth Sleepiness Scale, ESS),<sup>18</sup> cognition (Montreal Cognitive Assessment, MoCA initially; and then the Short Test of Mental Status, STMS),<sup>19,20</sup> and quality of life (Quality of Life in Epilepsy-10 items; QOLIE-10P).<sup>21</sup> We included discrete descriptions for the different auras, ictal states as well as postictal states,<sup>22</sup> medication history, surgical history, as well as device history. We discretized the EEG, magnetic resonance imaging (MRI), functional MRI (fMRI), positron emission tomography (PET), magnetic encephalography (MEG), and neuropsychological data, as well as laboratory results including antiseizure medication levels and cerebrospinal fluid (CSF) findings. Many of the fields and variables and forms that we employed were adapted from the NINDS Common Data Elements pertaining to epilepsy.<sup>12</sup> We also incorporated the Medical Research Council (MRC) Prognostic Index as a guideline for continuing or discontinuing antiseizure medication.<sup>23</sup> For the formulation of the impression, we included the 1989 and 2010 ILAE epilepsy classifications as well as new-onset seizure and psychogenic nonepileptic seizure definitions.<sup>13,14</sup> For the formulation of the plan, we included statements regarding seizure precautions, drug adverse events, drug interactions, and drug teratogenicity in accordance with the AAN quality measures.<sup>3</sup> We designed a workflow that included a medical assistant, nurse, neurologist, and research assistant (when applicable) to accomplish the above activities without extending the face-to-face time with the neurologist (typically 60 min at initial and annual follow-up visits).

## EMR building

After we had decided on the content and the workflow to accomplish our best practices, we met with programmer analysts on the NorthShore University HealthSystem EMR Optimization team. They built the SCDS and CDS tools required for clinical standardization, note writing, data capture, Best Practice Advisories (BPAs), and research enrollment. More specifically, the toolkits included custom

navigators (effectively, an index of electronic forms), electronic forms (documentation flow sheets, including cascading data elements and autoscoring and auto-interpreting and other “smart form” features), BPAs (pop-up boxes), and order sets. We also included optional free text and narrative fields. The epilepsy team met every 2 weeks with the EMR Optimization team for 3 months to develop and test the tools. Although the toolkits were designed primarily for initial and annual follow-up visits, they also provided the capability to support interval visit types (typically briefer, 30 min face-to-face time). Screenshots of these toolkits are provided in Figure 2 and Data S1.

## Implementation into clinical workflow

After the epilepsy toolkit was built, the neurologists tested them in the EMR development environment. Revisions were made as needed and the toolkit was moved to the EMR production environment to be used during patient visits. The epilepsy team continued to meet every 2 weeks to discuss patient encounters and to make additional changes to the toolkit. We also worked with programmer analysts of the Enterprise Data Warehouse (EDW) team to extract, transform, and load data from the EMR to epilepsy-specific data marts, and to develop monthly enrollment and follow-up reports (for patients enrolled in a DNA biobank) and monthly data quality reports (for required fields). The content building, EMR building, and implementation phases of the project took approximately 9 months total.

Specifically regarding our clinical workflow, when patients check in for their office visit for the first time with an epilepsy indication, or annually thereafter in follow-up, patient-support agents distribute the patient-reported outcome measures as paper forms for the patients to complete while in the waiting room. We considered pushing these forms out electronically prior to the office visits using the EMR’s patient portal, but less than half of the patients had active accounts, and the wait time for appointments in our department is brief (~1 week), allowing little time for previsit tasks. We considered using tablet or desktop computing devices to directly enter information into the EMR in the waiting areas, but decided against this as patients may have limited cognitive, motor, or sensory abilities, or may be unfamiliar with such electronic devices. Once the paper forms are completed, medical assistants review and enter the patient reported outcomes into an electronic version of the forms. Nurses then perform additional clinical assessments and enter information directly into the electronic forms to which they are assigned, reviewing also the work of the medical assistants who preceded them in the workflow. The neurologists then perform additional clinical assessments, entering information directly into the electronic forms to which they are assigned, reviewing also the work of the medical assistants and the nurses who preceded them in the workflow. We have attached to each initial and annual follow-up visit, a 30 min pre-neurologist resource

**A**

Is this the initial visit for spells or seizures or had there been spells or seizures since last visit  
 Yes  No  Don't know  
 Yes taken 6 months ago

**Spells/Seizures**

Are you documenting a new spell or seizure type  
 Yes  No  Don't know  
 Yes taken 6 months ago

Types of preceding aura  
 None  Sensory  Elementary  Somatosensory  Visual  Auditory  Olfactory  Gustatory  Epigastric  Cephalic  Autonomic  Experiential  Affective  Mnemonic  
 Hallucinatory  Illusory  Other  Don't know  
 Epigastric; Hallucinatory taken 6 months ago

Mode of onset  
 Generalized  Focal  Don't know  
 Focal taken 6 months ago

Symptoms during the spell or seizure  
 Tonic motor seizure  Epileptic spasm  Postural seizure  Versive seizure  Dystonic seizure  Myoclonic seizure  Negative myoclonic seizure  Clonic seizure  
 Jacksonian march  Tonic-clonic seizure  Generalized tonic-clonic seizure  Atonic seizure  Astatic seizure  Synchronous  Automatism  Oroalimentary automatism  
 Mimetic automatism  Manual or pedal automatism  Gestural automatism  Hyperkinetic automatism  Hypokinetic automatism  Dysphasic automatism  Dyspraxic automatism  
 Gelastic automatism  Dacrytic automatism  Vocal automatism  Verbal automatism  Spontaneous automatism  Interactive automatism  Dyscognitive  Other  Don't know  
 Dyscognitive; Verbal automatism taken 6 months ago

Is the order of symptom appearance known  
 Yes  No  N/A  Don't know  
 Yes taken 6 months ago

Is the duration of spell or seizure known  
 Yes  No  Don't know  
 Yes taken 6 months ago

Associated features  
 None  Occur in clusters  Tongue biting  Urinary incontinence  Other  Don't know  
 Tongue biting taken 6 months ago

History of prolonged spells or seizures or clusters (30 minutes or longer)  
 Yes  No  Don't know  
 Yes taken 6 months ago

Was patient admitted for the spell or seizure  
 Yes  No  Don't know  
 Yes taken 6 months ago

Post-ictal symptoms following the spell or seizure  
 N/A  None  Lateralizing phenomenon  Impaired cognition  Amnesia  Psychosis  Headache  Fatigue  Emesis  Other autonomic  Don't know  
 Impaired cognition; Fatigue taken 6 months ago

Trigger types  
 None  Missed medications  Missed meals  Eating  Sleep deprivation  Sleep  Stress  Fatigue  Fever  Menstrual cycle  Pregnancy  Alcohol use  Alcohol withdrawal  
 Drug use  Drug withdrawal  Heat  Bathing  Reading  Flashing lights  Other visual triggers  Music  Other  Don't know  
 Sleep deprivation; Stress taken 6 months ago

Currently experiencing this spell or seizure in the past year  
 Yes  No  Don't know  
 Yes taken 6 months ago

**B**

Sequences Obtained  
 Axial turbo / fast spin echo T2-weighted images (2 mm skip 0); whole brain  
 Coronal turbo / fast spin echo T2-weighted high resolution coronal oblique sequence (512 x 512, maximum slice thickness of 4 mm); whole brain  Coronal fast FLAIR T2-weighted  
 Sagittal or coronal 3D T1-weighted gradient echo volume sequence (256 x 256, maximum slice thickness of 1.5 mm)  Standard sagittal T1-weighted sequence images  Other  
 Don't know  
 Axial turbo / fast spin echo T2-weighted images (2 mm skip 0), whole brain; Coronal turbo / fast spin echo T2-weighted high resolution coronal oblique sequence (512 x 512, maximum slice thickness of 4 mm), whole brain; Coronal fast FLAIR T2-weighted; Sagittal or coronal 3D T1-weighted gradient echo volume sequence (256 x 256, maximum slice thickness of 1.5 mm); Standard sagittal T1-weighted sequence images taken 6 months ago

Year Scan Performed  
 Don't know  2016  2015  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  2002  2001  2000  1999  1998  1997  1996  1995  1994  1993  
 1992  1991  1990  1989  1988  1987  1986  1985  1984  1983  1982  1981  1980  
 2013 taken 6 months ago

Date Scan Performed

2. Imaging Normality  
 Normal  Abnormal  Incidental (not relevant for epilepsy evaluation)  Don't know  
 Abnormal taken 6 months ago

3. Lateralization  
 N/A  Left  Right  Bilateral  Don't know  
 Left taken 6 months ago

4. Distribution  
 N/A  Unifocal  Bilobar  Hemispheric  Multifocal  Diffuse / generalized  Other  Don't know  
 Multilobar taken 6 months ago

5a. Locations - Cortical  
 Basal occipital - left  Basal occipital - right  Dorsal lateral frontal - left  Dorsal lateral frontal - right  Dorsal lateral parietal - left  Dorsal lateral parietal - right  Frontal polar - left  
 Frontal polar - right  Insula - left  Insula - right  Lateral occipital - left  Lateral occipital - right  Lateral temporal - left  Lateral temporal - right  Mesial frontal - left  
 Mesial frontal - right  Mesial occipital - left  Mesial occipital - right  Mesial parietal - left  Mesial parietal - right  Mesial temporal - left  Mesial temporal - right  
 Orbital frontal - left  Orbital frontal - right  Temporal polar - left  Temporal polar - right  Other  Don't know  
 Dorsal lateral parietal - left taken 6 months ago

5b. Locations - Subcortical  
 Basal ganglia - left  Basal ganglia - right  Callosum - left  Callosum - right  Grey-white matter junction - left  Grey-white matter junction - right  Periventricular - left  
 Periventricular - right  Thalamus - left  Thalamus - right  White matter - other  Other  Don't know  
 Basal ganglia - left taken 6 months ago

6. Features  
 N/A  Agenesis  Atrophy  Cortical thinning  Cystic (including multicystic)  Decreased grey-white matter distinction  Dysgenesis (includes dysmorphology of cortical mantle)  
 Encephalomalacia  Heterotopic tissue versus migration abnormality  Hypertrophy  Hyperplasia (grey or white matter)  Hypoplasia (grey or white matter)  
 Loss of architecture (specific to hippocampus)  Malformation related white matter signal abnormality  Other  Don't know

7. Contrast enhancement  
 Yes  No  N/A  Don't know  
 Yes taken 6 months ago

8. Impression of Specific Abnormalities  
 N/A  Mesial Temporal Sclerosis  Malformation of cortical development (MCD)  Vascular abnormalities  Neoplasm  Inflammatory/infectious abnormalities  
 Atrophy or tissue loss  Other  Don't know  
 Mesial Temporal Sclerosis taken 6 months ago

Mesial temporal sclerosis (impression)  
 N/A  Hippocampal sclerosis  Hippocampal sclerosis plus inter-lateral temporal dysplasia/atrophy  Hippocampal sclerosis with remote dual pathology (i.e. remote lesion)  Other  
 Don't know

Figure 2.

Screenshots of the SDCD toolkits within the EMR, ©2015 EPIC Systems, used with permission. (A) Screenshot of spells/seizure data collection, (B) screenshot of diagnostic imaging data collection, (C) screenshot of EEG data collection, (D) screenshot of MRC Prognostic Index data collection. Additional screenshots are available in Data S1.

Epilepsia © ILAE



C

Scalp Electroencephalography

Scalp EEG  Yes, with report available  Yes, no report available  No  Don't know  
Yes, with report available taken 6 months ago

EEG Results  Normal  Abnormal  
Abnormal taken 6 months ago

Would you like to document specifics of EEG  Yes  No  
Yes taken 6 months ago

General EEG Information

Reason for EEG  Research purposes  Clinical purposes  Other  Don't know  
Clinical purposes taken 6 months ago

EEG recording year  Don't know  2018  2015  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  2002  2001  2000  1999  1998  1997  1996  1995  
1994  1993  1992  1991  1990  1989  1988  1987  1986  1985  1984  1983  1982  1981  1980  
2014 taken 6 months ago

EEG recording start date

EEG recording end date

EEG type  N/A  Routine  Prolonged  Other  Don't know  
Routine taken 6 months ago

EEG Location  Outpatient EEG lab  Inpatient Epilepsy Monitoring Unit (EMU)  Intensive Care Unit (ICU)  Ambulatory  Other  Don't know  
Outpatient EEG lab taken 6 months ago

EEG Video  Yes  No  Other  Don't know  
No taken 6 months ago

Behavioral states recorded  Awake  Asleep  Unresponsive state  Indeterminate  Other  Don't know  
Awake; Asleep taken 6 months ago

Activating procedures used  N/A  None  Sleep  Hyperventilation  Photic stimulation  Other  Don't know  
Hyperventilation; Photic stimulation taken 6 months ago

Posterior dominant rhythm present  Yes  No  Don't know  
Yes taken 6 months ago

>> Frequency of the posterior dominant rhythm during relaxed wakefulness (hertz)   
10 hertz taken 6 months ago

Total number of seizures recorded with EEG ONLY   
0 taken 6 months ago

Inter-ictal Abnormalities

Inter-ictal Abnormalities  Yes  No  Don't know  
Yes taken 6 months ago

Inter-ictal epileptiform location  Localized focal  Localized regional lobar or multi-lobar  Hemisphere - left  Hemisphere - right  Generalized  No localized onset  Other  Don't know  
Localized regional lobar or multi-lobar taken 6 months ago

>> Localized regional lobar or multilobar  Left Frontal  Right Frontal  Left Parietal  Right Parietal  Left Occipital  Right Occipital  Left Temporal  Right Temporal  Other  Don't know

Inter-ictal circumstances  Awake  Drowsy  Sleep  Hyperventilation  Photic stimulation  Indeterminate  Other  Don't know  
Awake; Drowsy; Sleep taken 6 months ago

Inter-ictal frequency  Frequent  Intermittent  Occasional  Rare  Don't know  
Frequent taken 6 months ago

Inter-ictal special patterns  None  PLEDS  BPEDS  Triphasic  Burst suppression  Complete suppression  Near complete suppression  Other  Don't know  
Triphasic taken 6 months ago

PLEDS comment

Triphasic comment

Ictal EEG Evaluation

Ictal Abnormalities  Yes  No  Don't know  
Yes taken 6 months ago

EEG Exam Date

Are ictal features the same for all seizures  Yes  No  Don't know

Ictal Video

Ictal onset: Location on EEG  Localized focal  Localized regional lobar or multi-lobar  Hemisphere - left  Hemisphere - right  Generalized  No localized onset  Other  Don't know

Full ictal propagation: Location on EEG  Localized focal  Localized regional lobar or multi-lobar  Hemisphere - left  Hemisphere - right  Generalized  No localized onset  Other  Don't know

Ictal onset: Pattern on EEG  N/A  None  Generalized tonic-clonic pattern  Diffuse Fast Rhythms  Diffuse Attenuation  Rhythmic  Paroxysmal discharges - sharp wave  Paroxysmal discharges - spikes  Paroxysmal discharges - single spike wave  Paroxysmal discharges - polyspike wave  Paroxysmal discharges - other  Don't know

Ictal onset: Circumstances  Awake  Drowsy  Sleep  Hyperventilation  Photic stimulation  Indeterminate  Other  Don't know  
Drowsy; Awake taken 6 months ago

Comments

Focal and Generalized Slowing

EEG Slowing  N/A  None  Focal slowing  Generalized slowing  Other  Don't know  
Focal slowing taken 6 months ago

>> Focal slowing type  Persistent (i.e. continuous)  Transient  Post-ictal  Other  Don't know  
Transient taken 6 months ago

>> Focal slowing location  Localized regional lobar or multi-lobar  Hemisphere - left  Hemisphere - right  Generalized  No localized onset  Other  Don't know  
Localized regional lobar or multi-lobar taken 6 months ago

>>>> Focal slowing lobar location  Left Frontal  Right Frontal  Left Parietal  Right Parietal  Left Occipital  Right Occipital  Left Temporal  Right Temporal  Other  Don't know  
Right Occipital; Right Frontal taken 6 months ago

Inter-ictal Attenuation

Inter-ictal attenuation  N/A  None  Focal attenuation  Generalized attenuation  Other  Don't know  
None taken 6 months ago

Impression

Impression

Clinical correlation

Figure 2. Continued  
Epilepsia © ILAE

**D**

MRC Prognostic Index			
Has patient been seizure-free for 2 years	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Don't know		
Yes taken 6 months ago			
MRC Prognostic Index			
Age 16 years or older	<input type="checkbox"/> Yes <input type="checkbox"/> No		
Yes taken 6 months ago			
Taking more than one epileptic drug	<input type="checkbox"/> Yes <input type="checkbox"/> No		
Yes taken 6 months ago			
Seizures after start of antiepileptic drug treatment	<input type="checkbox"/> Yes <input type="checkbox"/> No		
Yes taken 6 months ago			
History of primary or secondary generalized tonic-clonic seizures	<input type="checkbox"/> Yes <input type="checkbox"/> No		
Yes taken 6 months ago			
History of myoclonic seizures	<input type="checkbox"/> Yes <input type="checkbox"/> No		
Yes taken 6 months ago			
Electroencephalogram in past year	<input type="checkbox"/> Normal <input type="checkbox"/> Abnormal <input type="checkbox"/> Not available		
Abnormal taken 6 months ago			
Seizure Free Years (minimum 2 years)	<input type="text" value="3"/>	Period free from seizures score	<input type="text" value="66.67"/>
3 taken 6 months ago		66.67 (calculated) taken 6 months ago	
Total score	<input type="text" value="126.67"/>		
126.67 (calculated) taken 6 months ago			
Divide total score by 100 and exponentiate	<input type="text" value="3.55"/>		
3.55 (calculated) taken 6 months ago			
Percent probability of recurrence of seizure (over 1 year)			
With continued treatment	<input type="text" value="34"/>	With slow withdrawal	<input type="text" value="73"/>
34 % (calculated) taken 6 months ago		73 % (calculated) taken 6 months ago	
Percent probability of recurrence of seizure (over 2 years)			
With continued treatment	<input type="text" value="57"/>	With slow withdrawal	<input type="text" value="84"/>
57 % (calculated) taken 6 months ago		84 % (calculated) taken 6 months ago	

**Figure 2.**  
Continued  
Epilepsia © ILAE

visit, allowing the medical assistants and the nurses sufficient time to complete their portion of the customized care navigators. The neurologist is scheduled a 60 min visit to complete their portion of the customized care navigator. We also attach to each initial visit up to 30 additional minutes for care coordination and possible research enrollment into a biobank. We inform patients to plan to spend up to 120 min total for the initial visit, and up to 90 min for the annual follow-up visits. Note that for interval visits (between initial or annual visits), physicians may elect to use any or all of the electronic forms provided by the custom navigators, allowing flexibility in the use of the tools for such visits (scheduled for only 30 min). By requiring all electronic forms to be completed at initial and annual visits, we ensure clinical standardization according to best practices.

### Reporting—enrollment, quality, descriptive, analytical

After SCDS toolkit implementation, epileptologists met every 2 weeks with programmers specialized in extracting, transforming, and loading data from the EMR's relational data repository to project-specific data marts in North-Shore's EDW. The data marts provide an interface for analytic tools. Up to 1,000 fields of data were captured per office visit. EDW programmer analysts created monthly reports to track research enrollment in our DNA biobanking initiative (231 as of May 31, 2016). The enrollment reports are generated monthly. Reports indicate the number of participants by ethnicity and race or by month and year; the number of initial or follow-up visits per year; a listing of enrollees (including dates of consent and initial and follow-up visits, and annotations regarding death, withdrawal from

the study, invalid consent, screen failure, or pending blood draw); and a summary of longitudinal follow-up (including numbers of patients actively followed, past due, pending due, or not due; and follow-up rates).

EDW programmer analysts created monthly data quality reports that indicate which of the required data were missing for each office visit. These quality reports are distributed to the care team to input missing values. Data not cleaned within 3 months are archived as permanently missing, and those data are not listed on subsequent reports. The care team learned where they were error prone from the data quality reports, and they remediated their use of the toolkits. When systematic errors occurred for many providers, the team had the opportunity to improve their use of the toolkits or to request optimizations or a change in data requirements.

Once our epilepsy toolkit was under regular use, and after cleaned data were captured for at least 100 patients, our statistician developed quarterly descriptive reports of cohort characteristics (providing medians, ranges, and frequencies) to identify possible gaps in care.

We also developed quarterly score test analytic reports (pairwise correlations, principal component analyses) to explore the variation between the measures at initial visits, and to reduce the complexity of the toolkits when able (e.g., by removing highly correlated score tests).

### Quality improvement

We also developed quarterly quality improvement dashboards: interactive pivot tables that for defined quality initiatives allowed us to measure trends and stratify performance on factors such as the provider or the practice

site, or the age or gender of the patient. For epilepsy we are tracking quality improvement processes such as the following: (1) prescription of antidepressants or anxiolytics or referral to psychiatry or psychology or social services for depression and anxiety; (2) referral for neuropsychological testing in patients with cognitive impairment; (3) vitamin D supplementation for patients on antiepileptic medication to prevent osteoporosis/osteopenia; (4) folic acid supplementation in women of childbearing age and on antiepileptic medication to prevent teratogenesis.

Our multidisciplinary team (epileptologists, EMR programmers, EDW programmers, statistician, practice manager, research personnel) continues to meet every 2 months to improve all structures and processes (EMR tools, clinical workflows, data management, reports), to monitor patient outcomes, and to engage in quality improvement and practice-based research.

## RESULTS

We created SCDS toolkits within the EMR—the first step in our process for quality improvement and practice-based research in epilepsy (Fig. 1).<sup>10</sup> Some examples of the custom navigator and the electronic forms created are shown in Figure 2, and additional screenshots are provided in Data S1.

A complete descriptive cohort report (for 231 patients enrolled in our DNA biobank as of May 31, 2016) is provided in Data S2. These reports also show where there was no information collected/missing for each.

We also performed pairwise correlations (unadjusted and adjusted) of the scored tests at the initial visits of these 231 patients. A full analytical report for this cohort is provided in Data S3. We excluded from the analyses the MRC Prognostic Index, at it is available for only a subset of patients (seizure-free at 2 years) and as our sample size is limited for that stratum to date. The analyses included data for ESS, GAD-7, MoCA, NDDIE-E, and QOLIE-10P scores. More recently we switched from using the MoCA to the STMS to evaluate cognition (shorter test, fewer false-positive results, and no copyright restrictions for electronic use). We used published nomograms to convert MoCA scores to MMSE scores, and unpublished nomograms (courtesy of the Mayo Clinic, Dr. Bradley Boeve) to convert STMS scores to MMSE scores.

## DISCUSSION

SCDS and CDS tools built into the EMR can be used to standardize epilepsy office visits. This is expected to improve the quality of care by reinforcing adherence to best practices, by improving note writing, by hardwiring patient safety, and by providing descriptive and analytic reports and dashboards. Our initial reports indicate that the score

test measures that we are employing provide varying types of information, and our choice of measures is justified (efficiency). Our initial reports also indicate that there are many potential gaps in the quality of epilepsy care, including with respect to the following: (1) detecting and managing anxiety, depression, sleep disorders, and psychosocial stress, which are common in epilepsy patients and impact quality of life; (2) otherwise detecting and managing cognitive impairment; (3) detecting and managing osteoporosis and osteopenia; and (4) preventing teratogenesis. We are building additional BPAs to improve processes and hopefully patient outcomes.

The epilepsy toolkit has the potential to also support clinical research enrollment. For example, for patients with a diagnosis of epilepsy who are 18 or older and who live in Cook or Lake County, Illinois, a BPA pops up, indicating that the patient is eligible for enrollment in a DNA biobanking study.<sup>10</sup> If the neurologist selects “enroll,” an electronic message is sent to the research assistant assigned to the practice site alerting them to consent the patient and draw blood at the end of the office visit. The BPA also allows the research assistant to document the consenting process and biobanking procedures. If the neurologist selects “do not enroll,” a drop-down menu asks that the neurologist document a reason. All DNAs are genotyped for up to 1 million single nucleotide polymorphism markers, and we are associating the genotypes with the clinical data captured by the EMR (“clinomics”), toward the development of pharmacogenomic and molecular prognostic tests (thus far lacking in epilepsy).

We are also using the toolkit to implement pragmatic trials in epilepsy using subgroup-based adaptive (SUBA) designs.<sup>1,24</sup> We are comparing head-to-head, three commonly prescribed first-line antiepileptic medications, to see which are the most effective treatments for which subgroups of patients (precision medicine).<sup>10</sup> Our EMR tools initially randomize the first 100 eligible subjects to any of the three treatments. Our EMR tools then adaptively assign subsequent eligible subjects to the most effective treatment, factoring the independent and dependent variables captured for the individual subject by the SCDS tools, and the response of similar subjects to the compared treatments previously.

We are also sharing our epilepsy toolkit, free of charge, with other neurology departments that use the same EMR platform (Epic), and that agree to share the data captured, de-identified, in a data repository, thereby creating an NPBRN. The NPBRN currently includes 11 academic departments of neurology, and additional sites are being recruited. Together the NPBRN is engaging in a series of quality improvement and outcomes research studies across several areas of neurology, including epilepsy. This initiative is also being facilitated by the AAN.<sup>10</sup>

Our approach is not without challenges. The building of EMR tools or data registries can be prohibitively costly. We were able to build our toolkits at NorthShore using philanthropic and departmental research and development

funds, but we are making these tools available to participating NPBRN sites at no direct cost. All clinical workflow effort related to this initiative (medical assistants, nurses, neurologists) is paid for from the department's clinical practice account (sustainability). For subjects eligible for enrollment in our biobank, the research assistants' efforts to administer written informed consent and to draw blood, and laboratory expenses for DNA and plasma extraction and storage and for genotyping, are paid for by philanthropic and departmental research and development funds. Additional funds are available from the Agency for Healthcare Research and Quality (AHRQ) to support the implementation of toolkits at NPBRN sites, the sharing of data, and the creation and mining of a registry.

There are also different versions of EMR software in use across institutions. We built our toolkits so that they can be installed in the most recent version and in historical versions of our EMR platform (Epic systems). We are committed to updating our EMR toolkits with each updated version, as they have become the way we practice clinically. We have implemented toolkits in the current and historical versions of the EMR at our NPBRN sites.

Safeguards are also required with respect to the use of the tools and the quality of the data collected. We focused our results on 231 patients who were evaluated initially using the SCDS toolkit and enrolled in the DNA biobank (18 or older, residents of Cook and Lake County, Illinois, final diagnosis of epilepsy, physician accepted the enrollment BPA, patient agreed to participate, and with valid written informed consent; ~96% participation rate). We also used the toolkit to evaluate patients initially who were not enrolled in the biobank, or for interval visits, or for annual visits. In total we have used the epilepsy SCDS toolkit >800 times. The descriptive cohort report and score test analytic report included as appendices (Data S2 and S3) indicate for the 231 enrolled patients the frequency of missing values for each of the summarized fields and score tests. Overall, missing data were few except for components that were added later to the toolkit (e.g., Short Test of Mental Status), or removed from the toolkit (e.g., Montreal Cognitive Assessment), or for components that were not applicable for many patients (e.g., MRC prognostic score). To limit the impact of missing data, we distribute each month to the medical assistants, nurses, and neurologists data quality reports (which required fields were missing, for each initial and annual visit). Most providers have few or no missing values on their monthly reports. Data quality reports are also being distributed to the NPBRN sites via our web-based and secure data registry portal.

In conclusion we have designed an epilepsy toolkit within a commercial EMR that provides SCDS and CDS and which we hope will significantly improve the quality of epilepsy

care and facilitate practice-based research. We believe that our initiative can serve as a model for similar EMR-based quality improvement and practice-based research initiatives.<sup>25,26</sup> We encourage the development of similar epilepsy toolkits using common data elements across different EMR platforms, toward the creation of a network of networks.

## ACKNOWLEDGMENTS

The authors acknowledge the generous funding support of the Auxiliary of NorthShore University HealthSystem with respect to the initial building of electronic medical record (EMR) toolkits, and thank the medical assistants, nurses, neurologists, EMR Optimization and Enterprise Data Warehouse programmers, administrators, and research personnel at NorthShore University HealthSystem who contributed to the quality improvement and practice-based research initiative using the EMR. The authors also acknowledge funding support from the Agency for Healthcare Research and Quality (R01HS024057). Finally, the authors thank the neurology patients who inspire us to improve quality and to innovate our clinical practice every day.

## FUNDING

Targeted study funding is provided by the Agency for Healthcare Research and Quality grant 1R01HS024057-01 "Quality Improvement and Practice Based Research in Neurology Using the EMR," awarded to Dr. Demetrius M. Maraganore.

## DISCLOSURE

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

## REFERENCES

- Hesdorffer DC, Logroscino G, Benn EK, et al. Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota. *Neurology* 2011;76:23–27.
- Jacoby A, Snape D, Baker GA. Determinants of quality of life in people with epilepsy. *Neurol Clin* 2009;27:843–863.
- Fountain NB, Van Ness PC, Swain-Eng R, et al. Quality improvement in neurology: AAN epilepsy quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. *Neurology* 2011;76:94–99.
- Arif H, Buchsbaum R, Pierro J, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. *Arch Neurol* 2010;67:408–415.
- Bootsma HP, Ricker L, Hekster YA, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. *Seizure* 2009;18:327–331.
- Fakhoury TA, Hammer AE, Vuong A, et al. Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. *Epilepsy Behav* 2004;5:532–538.
- French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology* 2004;62:1252–1260.
- French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and



- Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology* 2004;62:1261–1273.
9. Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. *Health Technol Assess* 2007;11:iii–iv, ix–x, 1–134.
  10. Maraganore DM, Frigerio R, Kazmi N, et al. Quality improvement and practice-based research in neurology using the electronic medical record. *Neurol Clin Pract* 2015;5:419–429.
  11. American Academy of Neurology. Guidelines and quality measures. Available at: <https://www.aan.com/Guidelines> and <https://www.aan.com/practice/quality-measures>. Accessed June 2, 2016.
  12. National Institute of Neurological Disorders and Stroke. Common data elements. Available at: <http://www.commondataelements.ninds.nih.gov/>. Accessed June 2, 2016.
  13. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia* 2010;51:676–685.
  14. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. *Epilepsia* 1989;30:389–399.
  15. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia* 2005;46:470–472.
  16. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166:1092–1097.
  17. Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in epilepsy: a multicentre study. *Lancet Neurol* 2006;5:399–405.
  18. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991;14:540–545.
  19. Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. *Mayo Clin Proc* 1987;62:281–288.
  20. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53:695–699.
  21. Cramer JA, Perrine K, Devinsky O, et al. A brief questionnaire to screen for quality of life in epilepsy. The QOLIE 10. *Epilepsia* 1996;37:577–582.
  22. Blume WT, Luders HO, Mizrahi E, et al. Glossary of descriptive terminology for ictal semiology. Report of the ILAE Task Force on classification & terminology. *Epilepsia* 2001;42:1212–1218.
  23. Medical Research Council antiepileptic drug withdrawal study group. Prognostic index for recurrence of seizures after remission of epilepsy. *BMJ* 1993;306:1374–1378.
  24. Xu Y, Trippa L, Müller P, et al. Subgroup-based adaptive (SUBA) designs for multi-arm biomarker trials. *Stat Biosci* 2016;8:159–180.
  25. Cheng EM. Configuring electronic health records to meet the needs of neurologists: a case study. *Neurol Clin Pract* 2015;5:371–373.
  26. Bernat JL. Best advances of 2015: picks from the Neurology Today Editorial Advisory Board. *Neurol Today* 2016;16:23–27. Available at: [http://journals.lww.com/neurotodayonline/Fulltext/2016/01070/Best\\_Advances\\_of\\_2015\\_Picks\\_from\\_the\\_Neurology.1.aspx](http://journals.lww.com/neurotodayonline/Fulltext/2016/01070/Best_Advances_of_2015_Picks_from_the_Neurology.1.aspx). Accessed June 2, 2016.

## SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

**Data S1.** Screenshots of a structured clinical document support toolkit for Epilepsy clinical practice. ©2015 EPIC Systems, used with permission.

**Data S2.** Complete descriptive cohort report from the initial visits of 231 epilepsy patients.

**Data S3.** Complete score test analytic report from the initial visits of 231 epilepsy patients, revealing the nonparametric bar graph and Q–Q plot distributions of the scores, the pairwise correlations of the score test measures unadjusted and adjusted, and the principal component analyses of the score test measures (without and with Varimax rotation).